sotalol has been researched along with Adverse Drug Event in 11 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Inpatient antiarrhythmic drug initiation for atrial fibrillation is mandated for dofetilide (DF) and is often performed for sotalol (SL), particularly if proarrhythmia risk factors are present." | 7.81 | Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation. ( Agusala, K; Caprio, T; Kulkarni, C; Oesterle, A; Passman, R; Subacius, H, 2015) |
| "Inpatient antiarrhythmic drug initiation for atrial fibrillation is mandated for dofetilide (DF) and is often performed for sotalol (SL), particularly if proarrhythmia risk factors are present." | 3.81 | Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation. ( Agusala, K; Caprio, T; Kulkarni, C; Oesterle, A; Passman, R; Subacius, H, 2015) |
| "Sotalol is an attractive alternative antiarrhythmic to amiodarone in this younger patient population, given the latter's toxicity profile, but it may have proarrhythmic effects." | 1.51 | Efficacy and adverse effects of sotalol in adults with congenital heart disease. ( Celermajer, DS; Cordina, RL; McGuire, MA; Moore, BM, 2019) |
| "Presumptive treatment for hyperkalemia was started based on her initial electrocardiogram." | 1.39 | Life-threatening hyperkalemia: a potentially lethal drug combination. ( Gourineni, VC; Juvet, T; Ravi, S; Zarich, SW, 2013) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Pedersen, JM | 1 |
| Matsson, P | 1 |
| Bergström, CA | 1 |
| Norinder, U | 1 |
| Hoogstraate, J | 1 |
| Artursson, P | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Moore, BM | 1 |
| Cordina, RL | 1 |
| McGuire, MA | 1 |
| Celermajer, DS | 1 |
| Juvet, T | 1 |
| Gourineni, VC | 1 |
| Ravi, S | 1 |
| Zarich, SW | 1 |
| Agusala, K | 1 |
| Oesterle, A | 1 |
| Kulkarni, C | 1 |
| Caprio, T | 1 |
| Subacius, H | 1 |
| Passman, R | 1 |
| Braam, SR | 1 |
| Tertoolen, L | 1 |
| van de Stolpe, A | 1 |
| Meyer, T | 1 |
| Passier, R | 1 |
| Mummery, CL | 1 |
| Graff, C | 1 |
| Struijk, JJ | 1 |
| Matz, J | 1 |
| Kanters, JK | 1 |
| Andersen, MP | 1 |
| Nielsen, J | 1 |
| Toft, E | 1 |
| Takahara, A | 1 |
| Sugiyama, A | 1 |
| Hashimoto, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety Assessment for Sotalol Protocol in Outpatient Unit[NCT05418036] | Phase 4 | 110 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for sotalol and Adverse Drug Event
| Article | Year |
|---|---|
Covariate analysis of QTc and T-wave morphology: new possibilities in the evaluation of drugs that affect cardiac repolarization.
Topics: Adolescent; Adult; Algorithms; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Aza Compounds; Cardiov | 2010 |
10 other studies available for sotalol and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Bi | 2008 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Efficacy and adverse effects of sotalol in adults with congenital heart disease.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Australia; Child; Drug-Relate | 2019 |
Life-threatening hyperkalemia: a potentially lethal drug combination.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Diuretics; Drug-Related Side Effects and Adverse Reaction | 2013 |
Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Drug-Related Side Effects and Adverse Reac | 2015 |
Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes.
Topics: Animals; Cell Line; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; E | 2010 |
Reduction of repolarization reserve by halothane anaesthesia sensitizes the guinea-pig heart for drug-induced QT interval prolongation.
Topics: Action Potentials; Adrenergic beta-Antagonists; Algorithms; Anesthetics, Inhalation; Animals; Chroma | 2005 |